LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Inicio・Lista de Acciones・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Cerrado

SectorSalud

4.6 -1.08

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.44

Máximo

4.6

Métricas clave
By Trading Economics
Ingresos	31M -172M
Ventas	4.4M 19M
Margen de beneficio	-899.843
Empleados	800
EBITDA	44M -148M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 meses	+38.53% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-140M 2.4B
Apertura anterior	5.68
Cierre anterior	4.6

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

4.15 / 4.75 Soporte y Resistencia

Recursion Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

7 nov 2025, 21:06 UTC

Principales Movimientos del Mercado

JBS Down After Trump Calls for Probe into Meat-Packing Companies

8 nov 2025, 18:10 UTC

Ganancias

10 Defensive Stocks with Market-Beating Yields -- Barrons.com

8 nov 2025, 13:10 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 nov 2025, 12:00 UTC

Ganancias

Apple's iPhone Air Is a Marketing Win and a Sales Flop -- WSJ

8 nov 2025, 10:30 UTC

Ganancias

Why Car Insurers Are Under Pressure to Cut Rates -- Heard on the Street -- WSJ

8 nov 2025, 03:50 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 nov 2025, 03:41 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 nov 2025, 03:07 UTC

Adquisiciones, fusiones, absorciones

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 nov 2025, 22:36 UTC

Ganancias

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov 2025, 22:22 UTC

Ganancias

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q Net $210M >CSU.T

7 nov 2025, 22:03 UTC

Ganancias

Constellation Software 3Q EPS $9.89 >CSU.T

7 nov 2025, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

7 nov 2025, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

7 nov 2025, 20:59 UTC

Ganancias

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7 nov 2025, 20:26 UTC

Charlas de Mercado

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7 nov 2025, 20:22 UTC

Ganancias

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7 nov 2025, 20:04 UTC

Charlas de Mercado

Oil Futures Close Choppy Week With Losses -- Market Talk

7 nov 2025, 19:34 UTC

Charlas de Mercado

Gold Posts Small Gain for Week -- Market Talk

7 nov 2025, 19:31 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7 nov 2025, 19:17 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7 nov 2025, 19:09 UTC

Ganancias

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7 nov 2025, 19:08 UTC

Ganancias

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7 nov 2025, 18:31 UTC

Charlas de Mercado

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7 nov 2025, 17:27 UTC

Charlas de Mercado

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

7 nov 2025, 17:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Recursion Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

38.53% repunte

Estimación a 12 meses

Media 6.4 USD 38.53%

Máximo 8 USD

Mínimo 4.8 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Recursion Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Recursion Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

4.15 / 4.75Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.